Search / 576 results found

  • Updated

SEATTLE, Sept. 28, 2021 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it will present a poster on the company's new anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Virtual Special Conference: Tumor Immunology and Immunotherapy, to be held on October 5-6, 2021.